Efficacy of Proton-Pump Inhibitors in Children With Gastroesophageal Reflux Disease: A Systematic Review

@article{vanderPol2011EfficacyOP,
  title={Efficacy of Proton-Pump Inhibitors in Children With Gastroesophageal Reflux Disease: A Systematic Review},
  author={Rachel J. van der Pol and Marije J. Smits and Michiel P van Wijk and Taher I Omari and Merit Monique Tabbers and Marc A. Benninga},
  journal={Pediatrics},
  year={2011},
  volume={127},
  pages={925 - 935}
}
INTRODUCTION: Use of proton-pump inhibitors (PPIs) for the treatment of gastroesophageal reflux disease (GERD) in children has increased enormously. However, effectiveness and safety of PPIs for pediatric GERD are under debate. OBJECTIVES: We performed a systematic review to determine effectiveness and safety of PPIs in children with GERD. METHODS: We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews for randomized controlled trials and crossover studies investigating… Expand
Efficacy and Safety of Proton Pump Inhibitors in the Management of Pediatric Gastroesophageal Reflux Disease
TLDR
It is clear that further well‐designed trials and observational studies are needed to shed more light on the efficacy and safety of PPIs in the pediatric population. Expand
Comparative Safety and Efficacy of Proton Pump Inhibitors in Paediatric Gastroesophageal Reflux Disease
TLDR
The available data suggest that short-term use of PPIs is well tolerated and further well-designed trials and observational studies are still needed to clarify the efficacy and safety of PPI in the paediatric population, especially in infants under the age of 12 months. Expand
An update on the latest chemical therapies for reflux esophagitis in children
TLDR
Clinicians should reserve ASM use for infants and children with proven esophagitis and avoid their routine use in patients with merely symptoms of GER, and consider the controversies surrounding the use of PPIs in the pediatric population. Expand
Efficacy of proton pump inhibitors and H2 blocker in the treatment of symptomatic gastroesophageal reflux disease in infants
TLDR
The safety and efficacy of ranitidine and omeprazole have been demonstrated in infants and both groups of infants showed a statistically significant decrease in the score of clinical variables after the treatment. Expand
Proton Pump Inhibitors in Pediatrics
TLDR
Prolonged treatment of pediatric patients with PPIs has not caused cancer or significant abnormalities and the effectiveness of PPIs relates to their structures, which must undergo acidic activation within the parietal cell to allow the PPI to be ionized and form covalent disulfide bonds with cysteine bonds. Expand
ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
TLDR
Proton pump inhibitors or histamine H2 receptor antagonists may be used to treat children with gastroesophageal reflux disease, but not to treat asthma or unspecific symptoms. Expand
Proton Pump Inhibitors Therapy in Children with Gastroesophageal Reflux
TLDR
The use of P PI in children still needs further study and can not be inferred based on adult studies, so it is important to know the indications, side effects and safety of PPI therapy in children. Expand
Efficacy and safety of once-daily esomeprazole for the treatment of gastroesophageal reflux disease in neonatal patients.
TLDR
Signs and symptoms of GERD traditionally attributed to acidic reflux in neonates were not significantly altered by esomeprazole treatment and esome prazole was well tolerated and reduced esophageal acid exposure and the number of acidicReflux events in Neonates. Expand
Review of pantoprazole in pediatrics
TLDR
P pantoprazole was efficacious in resolving gastroesophageal reflux symptoms partially or completely in 1–16-year-old subjects and in healing erosive esophagitis, however, it was not effective in treating infants under 1 year of age with symptoms suggestive of GERD and because of unavailability of formulation appropriate for children younger than 5 years; it is not approved for use under this age. Expand
Safety of medication options for treating pediatric esophagitis
TLDR
Anti-secretory medications, mostly proton pump inhibitors, have substantially improved the management of pediatric esophagitis, Nevertheless, because of possible infectious safety concerns, their use must be restricted to validated indications only. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 81 REFERENCES
Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy
TLDR
GERD/ARC incidence increased for children of all ages between 2000 and 2005 and PPI initiations have now surpassed H2RA initiations. Expand
Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children
TLDR
This is the first prospective study performed in pediatric patients showing that the use of GA inhibitors was associated with an increased risk of acute gastroenteritis and community-acquired pneumonia in GERD-affected children. Expand
Clinical Response to 2 Dosing Regimens of Lansoprazole in Infants With Gastroesophageal Reflux
TLDR
Overall, there was no difference in the symptom response, as measured by I-GERQ-R scores, between 15 mg of lansoprazole given once per day and 7.5 mg given twice per day in infants with GERD, but the twice-daily regimen produced a faster symptom response. Expand
Proton Pump Inhibitor Utilization Patterns in Infants
TLDR
Examination of PPI use in the study population increased steadily from 1999 to 2004, and data offer valuable information on current PPI dosing patterns that may be used to design future clinical trials for assessment of gastroesophageal reflux disease regimens and clinical outcomes in the infant population. Expand
Effect of Omeprazole on Acid Gastroesophageal Reflux and Gastric Acidity in Preterm Infants With Pathological Acid Reflux
TLDR
Omeprazole is effective in reducing esophageal acid exposure in premature infants with pathological acid reflux on 24-h pH probe; however, the far more complex issues of safety and efficacy have yet to be addressed. Expand
Gastroesophageal Reflux in Children
TLDR
Clinical studies performed in adults and several studies involving children have demonstrated that the proton pump inhibitors are more effective than the histamine-2 receptor antagonists in the relief of GERD symptoms and healing of erosive esophagitis. Expand
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
TLDR
Preliminary data suggest that PPIs may be efficacious and safe for continuous use for up to 11 years' duration in children with underlying GERD-predisposing disorders. Expand
Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors
TLDR
Pediatric GERd/ARC patients incurred significantly higher healthcare costs compared to similar children without GERD/ARC as compared to patients initiated with H2RAs, which had more baseline comorbidities, and lower GERD-related HCC after beginning treatment. Expand
Current Pharmacological Management of Gastro-Esophageal Reflux in Children
TLDR
The levels of evidence adopted by the Centre for Evidence-Based Medicine in Oxford were used to assess the studies for all reported outcomes that were meaningful to clinicians making decisions about treatment, including the impact of clinical symptoms, pH study profile, and esophageal appearance at endoscopy. Expand
Long‐term use of proton pump inhibitors in GORD – help or hindrance?
  • G. Tytgat
  • Medicine, Biology
  • Alimentary pharmacology & therapeutics
  • 2001
TLDR
The therapeutic balance tips toward proton pump inhibitors for treatment of GORD because their limitations are largely surpassed by excellent clinical efficacy, tolerance, and lack of serious adverse effects. Expand
...
1
2
3
4
5
...